This is an investigational study. The combination of mFOLFOX6 and bevacizumab is FDA approved and commercially available for the treatment of colorectal cancer. Doxorubicin is FDA approved and commercially available for the treatment of ovarian cancer. Bevacizumab is FDA approved and commercially available for the treatment of colorectal cancer. Temsirolimus is FDA approved and commercially available for the treatment of renal cell carcinoma. NovoTTF is an FDA-approved device to treat glioblastomas.